Tensha Therapeutics is a Cambridge, Mass. company developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other disorders. Its lead program is a first-in-class small molecule currently in preclinical development targeting BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other malignancies. The company’s programs are based on discoveries from the laboratory of James Bradner, MD, at Dana-Farber Cancer Institute, and Tensha holds an exclusive license to that technology. Preclinical studies described in the company’s scientific background include JQ1’s activity in patient-derived cell lines and mouse xenograft models and inhibition of MYC-driven tumor growth. Tensha intends to advance its lead candidate through clinical proof-of-concept, lay the groundwork for clinical studies in other cancer indications, and pursue preclinical development of bromodomain inhibitors in areas outside oncology, including inflammatory and metabolic disorders. The company is positioned as a focused, capital-efficient organization funded by HealthCare Ventures.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2011